` SPARC (Sun Pharma Advanced Research Co Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

SPARC
vs
BSE Sensex 30

Over the past 12 months, SPARC has underperformed BSE Sensex 30, delivering a return of -33% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
SPARC vs BSE Sensex 30

Loading
SPARC
BSE Sensex 30
Add Stock
www.alphaspread.com

Performance Gap
SPARC vs BSE Sensex 30

Loading
SPARC
BSE Sensex 30
Difference
www.alphaspread.com

Performance By Year
SPARC vs BSE Sensex 30

Loading
SPARC
BSE Sensex 30
Add Stock

Competitors Performance
Sun Pharma Advanced Research Co Ltd vs Peers

BSE Sensex 30
SPARC
LLY
JNJ
NOVO B
ROG
Add Stock

Sun Pharma Advanced Research Co Ltd
Glance View

Market Cap
52.4B INR
Industry
Pharmaceuticals

Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.

SPARC Intrinsic Value
1 382.1 INR
Undervaluation 88%
Intrinsic Value
Price
S
Back to Top